Gilead Sciences (GILD) Return on Capital Employed (2009 - 2026)
Gilead Sciences' (GILD) quarterly Return on Capital Employed came in at 21.53% in Q1 2026, up 341.0% YoY from 4.88% in Q1 2025, and up 0.88% on a QoQ basis from 21.34% in Q4 2025.
Gilead Sciences (GILD) Return on Capital Employed (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Return on Capital Employed data on file, last reported at 21.53% in Q1 2026.
- Quarterly Return on Capital Employed rose 341.0% year-over-year to 21.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.53% (up 341.0% YoY) and the FY2025 annual result came in at 21.23%, up 1781.0% from the prior year.
- Return on Capital Employed climbed to 21.53% in Q1 2026, from 21.34% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 23.4% in Q3 2025 to a low of 1.94% in Q3 2024.
- A 5-year average of 13.79% and a median of 14.92% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 1444 bps — and 2025, when it soared 2146 bps.
- Tracing GILD's Return on Capital Employed over 5 years: stood at 14.2% in 2022, then increased by 5 bps to 14.92% in 2023, then plunged by 75 bps to 3.71% in 2024, then soared by 475 bps to 21.34% in 2025, then advanced by 1 bps to 21.53% in 2026.
- The last three Return on Capital Employed figures came in at 21.53% (Q1 2026), 21.34% (Q4 2025), and 23.4% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 17.83% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 17.92% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 9.96% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 16.76% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 16.66% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -5.97% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 11.86% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 11.42% |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 79.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.97% |
| Mar 31, 2026 | 21.53% |
| Dec 31, 2025 | 21.34% |
| Sep 30, 2025 | 23.40% |
| Jun 30, 2025 | 17.94% |
| Mar 31, 2025 | 18.12% |
| Dec 31, 2024 | 3.71% |
| Sep 30, 2024 | 1.94% |
| Jun 30, 2024 | 5.79% |
| Mar 31, 2024 | 3.42% |
| Dec 31, 2023 | 14.92% |
| Sep 30, 2023 | 16.39% |
| Jun 30, 2023 | 17.60% |
| Mar 31, 2023 | 17.00% |
| Dec 31, 2022 | 14.20% |
| Sep 30, 2022 | 11.48% |
| Jun 30, 2022 | 13.04% |
| Mar 31, 2022 | 12.68% |
| Dec 31, 2021 | 17.74% |
| Sep 30, 2021 | 20.30% |